Rybelsus vs Trulicity: Long-Term Durability of Response

Note: this article is pending qualified medical review. Treat exact trial figures as needing verification against the original publications before they inform a clinical decision.

What Durability Means in This Comparison

A medicine can lower HbA1c over a year, reduce cardiovascular events over several years and still be difficult for a particular person to keep taking. Those are related but different outcomes.

Before asking which drug lasts longer, identify the result you mean: maintaining glucose control, keeping weight below baseline, reducing cardiovascular risk or staying on a workable treatment. A trial addressing one of those questions does not automatically answer the others.

Rybelsus and Trulicity are also different products, not alternative names for the same medicine. Rybelsus contains semaglutide and Trulicity contains dulaglutide. Results from a branded oral tablet cannot be assumed to apply to an injectable or compounded semaglutide preparation. [5, 6]

The Direct Glycemic Comparison: PIONEER 10

PIONEER 10 enrolled 458 Japanese adults receiving background diabetes treatment. Participants received oral semaglutide 3 mg, 7 mg or 14 mg daily, or dulaglutide 0.75 mg weekly. The study lasted 52 weeks, and its primary endpoint concerned adverse events. HbA1c and weight changes were supportive secondary endpoints. [1]

Under the treatment-policy analysis, estimated HbA1c reductions were 1.7 percentage points with oral semaglutide 14 mg and 1.4 points with dulaglutide 0.75 mg. The corresponding average weight changes were a 1.6 kg loss and a 1.0 kg gain. These are group averages in that trial, not promised individual results. [1]

The comparison does not establish superiority against dulaglutide 1.5 mg, 3 mg or 4.5 mg, or in every population. Nor can one year of follow-up establish a five-year ranking between the drugs.

Why PIONEER 4 Cannot Answer the Trulicity Question

PIONEER 4 compared oral semaglutide with injectable liraglutide and placebo. It provides evidence about those treatments, but its findings cannot be relabeled as a semaglutide-versus-dulaglutide comparison. Recognizing the actual comparator prevents a convincing-looking trial name from supporting the wrong conclusion. [2]

Cardiovascular Outcomes: Both Have Relevant Evidence

REWIND randomized 9,901 adults to dulaglutide 1.5 mg weekly or placebo. Over a median 5.4 years, major cardiovascular events occurred in 12.0% and 13.4% respectively, with a hazard ratio of 0.88. Participants included people with previous cardiovascular disease and people with cardiovascular risk factors. [3]

SOUL randomized 9,650 adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both. Over a median 49.5 months, major cardiovascular events occurred in 12.0% receiving oral semaglutide and 13.8% receiving placebo; the hazard ratio was 0.86. [4]

Those studies establish benefits versus their own placebo groups. Comparing their hazard ratios does not prove that one medicine is better than the other: the populations, background treatment and follow-up differed.

What the Current Indications Say

Current U.S. prescribing information includes cardiovascular risk reduction for both treatments within their specified type 2 diabetes populations. The FDA approved the Rybelsus cardiovascular indication in October 2025. Its indication should therefore be evaluated alongside the SOUL evidence, rather than treating an older cardiovascular-safety trial as the entire oral-semaglutide evidence base. [5, 6, 7]

REWIND has longer median follow-up than SOUL, but follow-up length alone does not establish a treatment winner for an individual patient.

Weight Response and Continuing Treatment

The direct weight comparison above is specific to PIONEER 10 and its doses. Results from high-dose semaglutide obesity trials answer a different question and should not replace that comparison.

Follow-up should distinguish three patterns: an initial response that has stabilized, a rise in HbA1c despite continued use, and an apparent loss of effect after missed treatment or an access interruption. These patterns do not have the same explanation. Reviewing the timeline is more useful than assuming either drug inevitably stops working after a particular number of months.

The cited trials do not establish a universal weight-regain timetable after stopping either treatment. They also do not establish that every participant maintains the same response indefinitely.

Daily Tablets or a Weekly Injection?

Rybelsus requires morning administration on an empty stomach, with water and a wait before food, beverages or other oral medicines. Trulicity is a weekly injection that can be taken with or without food. These differences can affect which routine fits your life. [5, 6]

That practical observation is not evidence that fasting requirements caused a particular population's discontinuation rate, or that weekly injections always produce better adherence. A preference for tablets, a consistent morning routine, injection comfort and reliable access can point in different directions.

The current oral-semaglutide label also distinguishes Rybelsus tablets from Ozempic tablets. They have different strengths and are not interchangeable milligram for milligram. Check the actual dispensed formulation rather than converting a dose from the brand name alone. [5]

A Decision Table That Uses the Right Evidence

Switching Between the Two

The decision should address a specific problem, such as an inadequate response, an unworkable routine, adverse effects or loss of access. Cardiovascular benefit is not a reason to assume oral semaglutide has no relevant evidence.

The product labels do not provide one universal Rybelsus-to-Trulicity conversion. Existing oral and injectable semaglutide switching instructions cannot simply be transferred to dulaglutide. A switch needs a plan for the actual medicine and dose, not a general claim that all GLP-1 changes require no interval. [5, 6]

Tolerability and Access

Both labels describe gastrointestinal adverse effects and existing thyroid-tumor, pancreatitis and hypoglycemia considerations. Those subjects belong in an individual treatment assessment rather than a claim that either product is uniformly safer. [5, 6]

The cardiovascular trials also do not establish that every secondary kidney outcome improves. In SOUL, the confirmatory secondary outcomes were not significantly different between the groups. A favorable cardiovascular result should not be turned into a different indication. [4]

For access, compare the actual pharmacy price, coverage and the terms that apply to your prescription. A historical list price or savings-card example cannot establish today's out-of-pocket cost. An affordable treatment that remains available is part of durability in practice, but it does not change the trial results.

When to Seek Urgent Care Rather Than Wait for a Routine Follow-Up

Severe abdominal pain that persists, particularly if accompanied by vomiting, may suggest pancreatitis and requires immediate clinical assessment. Similarly, manifestations of severe allergic reaction, a palpable neck mass, ongoing hoarseness, or hypoglycemic symptoms that occur when dulaglutide is used alongside other diabetes agents all justify prompt contact with a healthcare provider rather than self-adjusting therapy.